색소침착 치료 시장 : 치료 유형별, 질환 유형별, 최종사용자별 : 세계 기회 분석과 산업 예측(2023-2032년)

Hyperpigmentation Treatment Market By Treatment Type, By Disorder Type, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,856,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,162,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계의 색소침착 치료 시장은 2022년에 51억 달러에 달하며, 2023-2032년에 CAGR 7.5%로 성장하며, 2032년까지는 105억 달러에 달할 것으로 예측되고 있습니다.

색소침착은 피부의 특정 부위가 검게 변색되는 것을 특징으로 하는 피부과 질환입니다. 피부색을 담당하는 색소인 멜라닌이 과도하게 생성되어 피부에 침착되어 발생합니다. 색소침착의 원인은 기미, 일광화상, 염증 후 색소침착, 노화 등 다양합니다. 색소침착의 효과적인 관리에는 종종 외용제, 레이저 치료, 화학적 필링이 포함되며, 증상이 더 악화되는 것을 막기 위해 햇볕에 노출되지 않도록 노력하는 경우가 많습니다.

색소침착 치료 시장의 성장은 전 세계 미용 기준의 변화와 노인 인구의 급격한 증가에 기인합니다. 최근 아름다움에 대한 사회적 인식이 눈에 띄게 변화하면서 투명하고 균일한 피부가 중요시되고 있습니다. 그 결과, 개인은 보다 완벽한 피부색을 추구하게 되었고, 이는 색소침착 치료에 대한 수요 증가에 기여하고 있습니다. 미디어의 영향과 소셜 플랫폼의 확산에 힘입어 진화하는 미의 기준은 기미 없는 피부가 건강과 매력의 상징으로 여겨지는 문화를 만들어냈습니다. 이러한 문화적 변화는 사람들이 피부 변색 문제를 해결하고 원하는 미적 감각을 얻기 위한 효과적인 솔루션을 찾기 위해 색소침착 치료의 채택이 급증하고 있습니다. 이러한 세계 미적 기준의 변화는 색소침착 치료 시장의 성장을 가속할 것으로 예상됩니다.

또한 노인 인구의 급격한 증가도 시장 성장에 크게 기여할 것으로 예상됩니다. 예를 들어 미국 인구 조사국에 따르면 노인 인구는 2020년에 5,580 만 명에 달할 것으로보고되었습니다. 세계 인구 통계가 계속 진화하고 노인의 비율이 증가함에 따라 색소침착증의 발생률은 더 높아질 것입니다. 피부가 검게 변하는 색소침착은 노년층에서 흔히 볼 수 있는 피부과적 문제이며, 햇빛 노출, 노화에 따른 변화, 기저 질환과 같은 요인으로 인해 발생하는 경우가 많습니다. 피부 외관을 개선하고 불규칙한 색소침착을 해결할 수 있는 솔루션을 찾는 노인 인구는 첨단 표적화된 색소침착 치료에 대한 수요를 촉진하고 있습니다. 제약 및 스킨케어 업계는 고령화 사회의 고유한 요구를 충족시키기 위해 특별히 조정된 혁신적인 제품과 치료법을 개발해 왔습니다. 그러나 화학적 필링과 광치료의 부작용이 시장 성장을 저해하는 요인으로 작용하고 있습니다.

색소침착 치료 시장은 치료 유형, 질환 유형, 최종사용자, 지역별로 분류됩니다. 치료 유형별로 시장은 외용제, 광선 요법, 미세 박피술로 분류됩니다. 질환 유형별로 시장은 노인성 기미, 기미, 기타로 분류됩니다. 기타에는 염증 후 색소침착, 여드름 흉터 등이 있습니다. 최종사용자에 따라 병원, 피부과 클리닉, 기타로 분류됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽), 아시아태평양(일본, 중국, 호주, 인도, 한국, 기타 아시아태평양), 라틴아메리카(브라질, 콜롬비아, 아르헨티나, 기타 라틴아메리카), 중동 및 아프리카(중동), 기타 라틴아메리카), 중동 및 아프리카A(GCC, 남미, 북아프리카, 기타 중동 및 아프리카A 지역)로 분석됩니다.

이해관계자 주요 이점

• 이 보고서는 2022-2032년 색소침착 치료 시장 분석 시장 부문, 현재 동향, 추정 및 동향, 역학에 대한 정량적 분석을 제공하여 우세한 색소침착 치료 시장 기회를 식별합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급자와 구매자의 네트워크를 강화할 수 있도록 구매자와 공급자의 잠재력을 밝힙니다.
• 색소침착 치료 시장 세분화를 자세히 분석하여 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 매출 기여도에 따라 매핑되어 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치에 대한 명확한 이해를 제공합니다.
• 이 보고서에는 지역별 및 세계 색소침착 치료 시장 동향, 주요 기업, 시장 부문, 용도 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

이 보고서에서 가능한 커스터마이징(추가 비용 및 일정에 대해는 영업 담당자에게 문의)

• 규제 가이드라인
• 고객의 관심사에 따른 기업 개요 추가
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 개요 확장 리스트
• 과거 시장 데이터
• 주요 기업의 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 주요 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회

제4장 색소침착 치료 시장 : 치료 유형별

• 개요
• 국소제
• 광 치료
• 마이크로더마브레이션

제5장 색소침착 치료 시장 : 질환 유형별

• 개요
• 검버섯
• 기미
• 기타

제6장 색소침착 치료 시장 : 최종사용자별

• 개요
• 병원
• 피부과 클리닉
• 기타

제7장 색소 증량 치료 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 콜롬비아
  • 아르헨티나
  • 기타 라틴아메리카
• 중동 및 아프리카
  • GCC
  • 남아프리카공화국
  • 북아프리카
  • 기타 중동 및 아프리카

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• Episciences Inc
• Vivier Pharma
• Pierre Fabre S.A
• L'Oreal Group
• Areolase Corporation
• Lyma
• Trophy Skin
• Bio Italica
• PCA Skin
• Procter & Gamble

KSA

영문 목차

영문목차

The global hyperpigmentation treatment market was valued at $5.1 billion in 2022, and is projected to reach $10.5 billion by 2032, growing at a CAGR of 7.5% from 2023 to 2032. Hyperpigmentation is a dermatological condition characterized by the darkening or discoloration of certain areas of the skin. This phenomenon occurs when an excess amount of melanin, the pigment responsible for skin color, is produced and deposited in the skin. There are various causes of hyperpigmentation such as Melasma, sun exposure, post inflammatory hyperpigmentation, and age factor. Effective management of hyperpigmentation often involves the use of topical treatments, laser therapy, or chemical peels, along with diligent sun protection to prevent further exacerbation of the condition

The hyperpigmentation treatment market growth is attributed to changes in beauty standards globally, and surge in geriatric population. In recent years, there has been a notable shift in societal perceptions of beauty, with an increasing emphasis on clear, even-toned skin. As a result, individuals are now more inclined toward achieving a flawless complexion, contributing to the heightened demand for hyperpigmentation treatments. The evolving beauty standards, fueled by media influence and the pervasive use of social platforms, have created a culture where blemish-free skin is considered a symbol of health and attractiveness. This cultural shift has led to a surge in the adoption of hyperpigmentation treatments as people seek effective solutions to address skin discoloration issues and attain the desired aesthetic. Thus, the change in beauty standards globally is expected to drive the growth of the hyperpigmentation treatment market.

In addition, the surge in geriatric population is expected to significantly contribute to the growth of the market. For instance, according to the U.S. Census Bureau, it was reported that the older population reached 55.8 million in 2020. As the global demographic landscape continues to evolve, with an increasing proportion of elderly individuals, the incidence of hyperpigmentation disorders becomes more prevalent. Hyperpigmentation, characterized by darkened areas of the skin, is a common dermatological concern among the elderly, often attributed to factors such as sun exposure, age-related changes, and underlying medical conditions. The geriatric population seeking solutions to enhance skin appearance and address pigmentation irregularities, has fueled the demand for advanced and targeted hyperpigmentation treatments. The pharmaceutical and skincare industries have developed innovative products and therapies specifically tailored to cater to the unique needs of the aging population. However, side effects associated with the chemical peels and photo therapy restrain the growth of the market.

The hyperpigmentation treatment market is segmented on the basis of treatment type, disorder type, end user, and region. By treatment type, the market is classified into topical agent, photo therapy, and microdermabrasion. By disorder type, the market is divided into age spots, melasma, and others. Others include post-inflammatory hyperpigmentation and acne scars. By end user, it is segregated into hospitals, dermatological clinics, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA).

Major key players that operate in the hyperpigmentation treatment market are Episciences Inc, Vivier Pharma, Pierre Fabre S.A, L'Oreal Paris, Areolase Corporation, Lyma, Trophy Skin, Bio Italica, PCA Skin and Procter & Gamble. Key players have adopted product launch as a key developmental strategy to improve the product portfolio of the hyperpigmentation treatment market

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hyperpigmentation treatment market analysis from 2022 to 2032 to identify the prevailing hyperpigmentation treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the hyperpigmentation treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global hyperpigmentation treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Treatment Type

• Topical Agent
• Photo Therapy
• Microdermabrasion

By Disorder Type

• Age Spot
• Melasma
• Other

By End User

• Hospitals
• Dermatological clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Colombia
  • Argentina
  • Rest Of La
• Middle East and Africa
  • Gcc
  • South Africa
  • North Africa
  • Rest Of Mea

Key Market Players:

• Episciences Inc
• Vivier Pharma
• Pierre Fabre S.A
• L'Oreal Group
• Areolase Corporation
• Lyma
• Trophy Skin
• Bio Italica
• PCA Skin
• Procter & Gamble

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Topical Agent
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Photo Therapy
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Microdermabrasion
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Age Spot
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Melasma
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Other
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: HYPERPIGMENTATION TREATMENT MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospitals
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Dermatological clinics
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Others
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: HYPERPIGMENTATION TREATMENT MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Treatment Type
  • 7.2.3. Market size and forecast, by Disorder Type
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Treatment Type
    • 7.2.5.1.2. Market size and forecast, by Disorder Type
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Treatment Type
    • 7.2.5.2.2. Market size and forecast, by Disorder Type
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Treatment Type
    • 7.2.5.3.2. Market size and forecast, by Disorder Type
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Treatment Type
  • 7.3.3. Market size and forecast, by Disorder Type
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Treatment Type
    • 7.3.5.1.2. Market size and forecast, by Disorder Type
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Treatment Type
    • 7.3.5.2.2. Market size and forecast, by Disorder Type
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Treatment Type
    • 7.3.5.3.2. Market size and forecast, by Disorder Type
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Treatment Type
    • 7.3.5.4.2. Market size and forecast, by Disorder Type
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Treatment Type
    • 7.3.5.5.2. Market size and forecast, by Disorder Type
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Treatment Type
    • 7.3.5.6.2. Market size and forecast, by Disorder Type
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Treatment Type
  • 7.4.3. Market size and forecast, by Disorder Type
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Treatment Type
    • 7.4.5.1.2. Market size and forecast, by Disorder Type
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Treatment Type
    • 7.4.5.2.2. Market size and forecast, by Disorder Type
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Treatment Type
    • 7.4.5.3.2. Market size and forecast, by Disorder Type
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Treatment Type
    • 7.4.5.4.2. Market size and forecast, by Disorder Type
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Treatment Type
    • 7.4.5.5.2. Market size and forecast, by Disorder Type
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Treatment Type
    • 7.4.5.6.2. Market size and forecast, by Disorder Type
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. Latin America
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Treatment Type
  • 7.5.3. Market size and forecast, by Disorder Type
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Treatment Type
    • 7.5.5.1.2. Market size and forecast, by Disorder Type
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. Colombia
    • 7.5.5.2.1. Market size and forecast, by Treatment Type
    • 7.5.5.2.2. Market size and forecast, by Disorder Type
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. Argentina
    • 7.5.5.3.1. Market size and forecast, by Treatment Type
    • 7.5.5.3.2. Market size and forecast, by Disorder Type
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. Rest Of La
    • 7.5.5.4.1. Market size and forecast, by Treatment Type
    • 7.5.5.4.2. Market size and forecast, by Disorder Type
    • 7.5.5.4.3. Market size and forecast, by End User
• 7.6. Middle East and Africa
  • 7.6.1. Key market trends, growth factors and opportunities
  • 7.6.2. Market size and forecast, by Treatment Type
  • 7.6.3. Market size and forecast, by Disorder Type
  • 7.6.4. Market size and forecast, by End User
  • 7.6.5. Market size and forecast, by country
    • 7.6.5.1. Gcc
    • 7.6.5.1.1. Market size and forecast, by Treatment Type
    • 7.6.5.1.2. Market size and forecast, by Disorder Type
    • 7.6.5.1.3. Market size and forecast, by End User
    • 7.6.5.2. South Africa
    • 7.6.5.2.1. Market size and forecast, by Treatment Type
    • 7.6.5.2.2. Market size and forecast, by Disorder Type
    • 7.6.5.2.3. Market size and forecast, by End User
    • 7.6.5.3. North Africa
    • 7.6.5.3.1. Market size and forecast, by Treatment Type
    • 7.6.5.3.2. Market size and forecast, by Disorder Type
    • 7.6.5.3.3. Market size and forecast, by End User
    • 7.6.5.4. Rest Of Mea
    • 7.6.5.4.1. Market size and forecast, by Treatment Type
    • 7.6.5.4.2. Market size and forecast, by Disorder Type
    • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Episciences Inc
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Vivier Pharma
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Pierre Fabre S.A
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. L'Oreal Group
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Areolase Corporation
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Lyma
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Trophy Skin
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Bio Italica
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. PCA Skin
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Procter & Gamble
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments

관련자료